Evidence map›Paper›PMID 26965540›Full record

Trial reportJournal of the American College of Cardiology2016

Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study.

Gabriel C Brooks, Byron K Lee, Rajni Rao, Feng Lin, Daniel P Morin, Steven L Zweibel, Alfred E Buxton, Mark J Pletcher, Eric Vittinghoff, Jeffrey E Olgin and 1 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03022877 (Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions), which is not on this map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03022877 nawithdrawnnot on this mapstarted 2017, after this paper: background citation

Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions

TypeinterventionalSponsorRWTH Aachen UniversityRan2017 to 2018Enrolled0ConditionsMyocardial Infarction, OutcomeArmsLevosimendan
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Wearable Cardioverter-Defibrillator after Myocardial Infarction.The New England journal of medicine · 2018
    Trial
  4. Trial
  5. Review
  6. Prognostic impact of cardiac dysfunctions in patients with ST-segment elevation myocardial infarction.American heart journal plus : cardiology research and practice · 2025
    Article
  7. Article
  8. Observational
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Predictive factors of left ventricular ejection fraction improvement after myocardial infarction treated invasively.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2023
    Article
  16. Article
  17. Predicting left ventricular functional recovery in ischaemic cardiomyopathy: needs and challenges.European heart journal supplements : journal of the European Society of Cardiology · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Gabriel C BrooksDepartment of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, California.
Byron K LeeDepartment of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, California.
Rajni RaoDepartment of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, California.
Feng LinDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Daniel P MorinDepartment of Medicine, Ochsner Medical Center, New Orleans, Louisiana; Ochsner Clinical School, University of Queensland School of Medicine, New Orleans, Louisiana.
Steven L ZweibelDepartment of Medicine, Hartford Hospital, Hartford, Connecticut.
Alfred E BuxtonDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Mark J PletcherDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Eric VittinghoffDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
Jeffrey E OlginDepartment of Medicine, Division of Cardiology, University of California San Francisco, San Francisco, California. Electronic address: jeffrey.olgin@ucsf.edu.
PREDICTS Investigators
University of California, San Francisco · USBrigham and Women's Hospital · USHartford Hospital · USOchsner Medical Center · US

Funding

A Clinical Coordinating Center for VEST and PREDICTSU01HL089458 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OLGIN, JEFFREY E · 2007 to 2010
$3.1M
Data Coordinating Center for VEST and PREDICTSU01HL089145 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLETCHER, MARK J · 2007 to 2010
$2.4M
NHLBI NIH HHS U01 HL089145NHLBI NIH HHS U01-HL089145NHLBI NIH HHS U01 HL089458NHLBI NIH HHS U01-HL089458
6 · The paper itself

Abstract

backgroundPersistent severe left ventricular (LV) systolic dysfunction after myocardial infarction (MI) is associated with increased mortality and is a class I indication for implantation of a cardioverter-defibrillator.

objectivesThis study developed models and assessed independent predictors of LV recovery to >35% and ≥50% after 90-day follow-up in patients presenting with acute MI and severe LV dysfunction.

methodsOur multicenter prospective observational study enrolled participants with ejection fraction (EF) of ≤35% at the time of MI (n = 231). Predictors for EF recovery to >35% and ≥50% were identified after multivariate modeling and validated in a separate cohort (n = 236).

resultsIn the PREDICTS (PREDiction of ICd Treatment Study) study, 43% of patients had persistent EF ≤35%, 31% had an EF of 36% to 49%, and 26% had an EF ≥50%. The model that best predicted recovery of EF to >35% included EF at presentation, length of stay, prior MI, lateral wall motion abnormality at presentation, and peak troponin. The model that best predicted recovery of EF to ≥50% included EF at presentation, peak troponin, prior MI, and presentation with ventricular fibrillation or cardiac arrest. After predictors were transformed into point scores, the lowest point scores predicted a 9% and 4% probability of EF recovery to >35% and ≥50%, respectively, whereas profiles with the highest point scores predicted an 87% and 49% probability of EF recovery to >35% and ≥50%, respectively.

conclusionsIn patients with severe systolic dysfunction following acute MI with an EF ≤35%, 57% had EF recovery to >35%. A model using clinical variables present at the time of MI can help predict EF recovery.

Indexed as

Ventricular RemodelingDisease ProgressionEchocardiographyFemaleHumansMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPrognosisProspective StudiesSeverity of Illness IndexStroke VolumeSurvival RateSystoleVentricular Dysfunction, Leftheart failureremodelingrisk assessmentventricular ejection fraction

Identifiers

PMID26965540
PMCPMC4854198
OpenAlexW2295123044

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.